EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

Jason J Luke iD, Diwakar Davar iD, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody, Jason Chesney iD, Robert Coffin, Thierry de Baere, Tanja D de Gruijl, Matthew Fury, Gregory Goldmacher iD, Kevin J Harrington iD und 14 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Jason J Luke und 25 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA lukejj@upmc.edu. Hauptthemen laut MEDLINE: Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite their potential, these therapies have had limited success in late-phase trials for advanced cancer resulting in few formal approvals. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to determine how to design clinical trials with the greatest chance of demonstrating the benefits of intratumoral immunotherapy for patients with cancers across all stages of pathogenesis.

Methods

An Intratumoral Immunotherapy Clinical Trials Expert Panel composed of international key stakeholders from academia and industry was assembled. A multiple choice/free response survey was distributed to the panel, and the results of this survey were discussed during a half-day consensus meeting. Key discussion points are summarized in the following manuscript.

Results

The panel determined unique clinical trial designs tailored to different stages of cancer development—from premalignant to unresectable/metastatic—that can maximize the chance of capturing the effect of intratumoral immunotherapies. Design elements discussed included study type, patient stratification and exclusion criteria, indications of randomization, study arm determination, endpoints, biological sample collection, and response assessment with biomarkers and imaging. Populations to prioritize for the study of intratumoral immunotherapy, including stage, type of cancer and line of treatment, were also discussed along with common barriers to the development of these local treatments.

Conclusions

The SITC Intratumoral Immunotherapy Clinical Trials Expert Panel has identified key considerations for the design and implementation of studies that have the greatest potential to capture the effect of intratumorally delivered immunotherapies. With more effective and standardized trial designs, the potential of intratumoral immunotherapy can be realized and lead to regulatory approvals that will extend the benefit of these local treatments to the patients who need them the most.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNeoplasms, Second PrimaryHumansImmunotherapySocieties, MedicalTumor Microenvironment

Stichwörter der Autor:innen

Clinical Trials as TopicGuidelines as TopicImmunotherapyMelanoma

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA lukejj@upmc.edu.
  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • HiFiBiO Therapeutics, Cambridge, Massachusetts, USA.
  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA.

ORCID-Profile: Jason J Luke, Diwakar Davar, Jason Chesney, Gregory Goldmacher, Kevin J Harrington, Ignacio Melero, Mark Middleton, Bart Neyns, David J Pinato, Rahul A Sheth, Aurelien Marabelle

Zitieren

APA

Luke, J. J., Davar, D., Andtbacka, R. H., Bhardwaj, N., Brody, J. D., Chesney, J., Coffin, R., de Baere, T., de Gruijl, T. D., Fury, M., Goldmacher, G., Harrington, K. J., Kaufman, H., Kelly, C. M., Khilnani, A. D., Liu, K., Loi, S., Long, G. V., Melero, I., …, & Marabelle, A. (2024). Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008378

Vancouver

Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, et al. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008378

BibTeX
@article{Luke2024,
  author = {Luke, Jason J and Davar, Diwakar and Andtbacka, Robert H and Bhardwaj, Nina and Brody, Joshua D and Chesney, Jason and Coffin, Robert and de Baere, Thierry and de Gruijl, Tanja D and Fury, Matthew and Goldmacher, Gregory and Harrington, Kevin J and Kaufman, Howard and Kelly, Ciara M and Khilnani, Anuradha D and Liu, Ke and Loi, Sherene and Long, Georgina V and Melero, Ignacio and Middleton, Mark and Neyns, Bart and Pinato, David J and Sheth, Rahul A and Solomon, Stephen B and Szapary, Philippe and Marabelle, Aurelien},
  title = {Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008378}
}
Kostenlos starten →